CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 127 enrolled
Drug / intervention
R-CHOP with doxorubicindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02916316
NCT02916316N/ACompleted
CompareCT.gov

Prospective Observational Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell

Fondazione Italiana Linfomi - ETS·observational·Posted Sep 27, 2016·Updated Nov 18, 2025

In Brief

An observational study evaluating R-CHOP with doxorubicin for Lymphoma and 2 related conditions. Completed, enrolled 127 participants across 18 sites.

Detailed Summary

All patients enrolled in the study will have to be treated with a chemo immunotherapy scheme R-CHOP with doxorubicin, with doxorubicin analogue or non pegylated liposomal anthracycline (R-COMP; Sec. 648 DM) administered every 21 days for 6 cycles. In unfavourable patients (stage II-IV) are allowed 2 additional cycles of rituximab at the end of the 6 cycles of R-CHOP.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Large B-Cell, Diffuse Large B-Cell
CountriesItaly
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 27, 2016
Enrollment StartFeb 12, 2014
Primary CompletionDec 30, 2020
Study CompletionDec 31, 2024
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 9.8 years ago

Interventions

R-CHOP with doxorubicindrug

Chemoimmunotherapy every 21 days for 6 cycles. In unfavourable patients (stage II-IV) are allowed 2 additional cycles of rituximab at the end of the 6 cycles of R-CHOP.